玻璃体腔注射贝伐珠单抗可提高小梁切除术后3年生存率:贝伐珠单抗在小梁切除术研究中的长期随访
该单中心、平行、双盲、随机安慰剂对照试验评估了小梁切除术联合丝裂霉素C(MMC)术中单次玻璃体腔注射贝伐珠单抗(1.25 mg/0.05 mL)对手术成功率的影响。共随机131例(贝伐珠单抗组65例,安慰剂组66例),111例完成36个月随访。36个月时贝伐珠单抗组小梁切除术生存率更高(完全成功HR=0.17,P=0.002;条件成功HR=0.07,P=0.03),安慰剂组在3、6、12、36个月时对局部降眼压药物的需求更高。结论:术中单次玻璃体腔注射贝伐珠单抗可改善联合MMC小梁切除术后36个月的手术成功率。
要点
- 术中单次玻璃体腔注射贝伐珠单抗(1.25 mg)可提高小梁切除术联合MMC的3年手术生存率。
- 36个月时完全成功HR=0.17(P=0.002),条件成功HR=0.07(P=0.03),均支持贝伐珠单抗组。
- 安慰剂组在3、6、12、36个月时局部降眼压药物使用需求更高。
核心结论
- 小梁切除术联合MMC术中单次玻璃体腔注射贝伐珠单抗(1.25 mg/0.05 mL)可改善术后36个月的手术成功率。
研究设计与样本
- 单中心、平行、双盲、随机、安慰剂对照试验,纳入需行初次或再次小梁切除术或青光眼白内障联合手术的进展性青光眼患者。
- 共随机131例,贝伐珠单抗组65例,安慰剂组66例;111例(85%)完成36个月随访。
- 贝伐珠单抗组术中接受单次玻璃体腔注射Avastin 1.25 mg/0.05 mL,安慰剂组接受平衡盐溶液0.05 mL。
主要发现
- 36个月时贝伐珠单抗组小梁切除术生存率高于安慰剂组:完全成功HR=0.17(P=0.002),条件成功HR=0.07(P=0.03)。
- 安慰剂组在3个月(P=0.008)、6个月(P=0.009)、12个月(P=0.007)、36个月(P<0.005)时对局部降眼压药物的需求更高。
关键数值与推荐
- 主要结局为治疗成功:完全成功定义为眼压低于预设目标值且无需局部降眼压药物;条件成功定义为需局部药物才能达到预设目标眼压。
临床怎么用
- 对于需行小梁切除术联合MMC的进展性青光眼患者,可考虑术中单次玻璃体腔注射贝伐珠单抗(1.25 mg/0.05 mL)以改善长期手术成功率。
局限性
- 单中心研究,样本量有限(随机131例,完成36个月随访111例),外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effect of a single intraoperative dose of intravitreal bevacizumab (Avastin) on surgical success after trabeculectomy with mitomycin-C (MMC) over 3 years. DESIGN: Single-center, parallel, double-masked, randomized, placebo-controlled trial. The setting was a single ophthalmic outpatient referral center within a tertiary teaching hospital. PARTICIPANTS: Patients requiring primary or redo trabeculectomy or phacotrabeculectomy for progressing glaucoma. Patients were randomized to a single intraoperative intravitreal injection of Avastin (1.25 mg in 0.05 mL) or placebo (balanced salt solution 0.05 mL). MAIN OUTCOME MEASURE: The primary outcome was treatment success, which was defined by "complete success" when intraocular pressure (IOP) remained less than a predefined target IOP without the requirement of topical medication or "qualified success" when topical medication was required to meet the predefined target IOP threshold. RESULTS: From a total of 131 patients randomized to bevacizumab (Avastin; n = 65) or placebo (n = 66), 111 patients completed 36 months of follow-up (85%). At 36 months, trabeculectomy survival was higher in the bevacizumab cohort (hazard ratio [complete success] = 0.17, P = 0.002; [qualified success] = 0.07, P = 0.03). Within the placebo cohort, the requirement for topical therapy was higher at 3 months (P = 0.008), 6 months (P = 0.009), 12 months (P = 0.007), and 36 months (P < 0.005). CONCLUSIONS: Bevacizumab was given as a single intravitreal dose during trabeculectomy with MMC resulting in improved surgical success at 36 months postoperatively. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Landers J, Mullany S, Hassall MM, et al. Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years: Long-term Follow-up from the Bevacizumab in Trabeculectomy Study. Ophthalmology. 2026. PMID: 42134554. doi:10.1016/j.ophtha.2026.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。